TetraLogic Pharmaceuticals Corporation (TLOG) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 4.06: the stock has moved about 306% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerTetraLogic Pharmaceuticals Corporation (TLOG) trades at $0.0001. TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology and infectious diseases. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for TLOG: TLOG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
TetraLogic Pharmaceuticals Corporation (TLOG) Healthcare & Pipeline Overview
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company developing small molecule therapeutics for oncology and infectious diseases, with a focus on apoptosis-inducing agents and histone deacetylase inhibitors. Their pipeline includes birinapant and SHAPE, targeting unmet needs in cancer treatment, positioning them within a competitive biotechnology landscape.
What Is the Investment Thesis for TLOG?
TetraLogic Pharmaceuticals Corporation presents a high-risk, high-reward investment profile typical of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of birinapant and SHAPE. Positive clinical trial results for either candidate could significantly increase the company's valuation. However, the company's reliance on a limited pipeline and the inherent uncertainties of drug development pose substantial risks. Investors should closely monitor clinical trial progress, regulatory milestones, and the company's cash runway. Given the current market capitalization of $0.00B, any positive news flow could lead to outsized gains, but failure to achieve clinical or regulatory success could result in significant losses. The high beta of 4.06 reflects the stock's volatility and sensitivity to market movements.
Based on FMP financials and quantitative analysis
TLOG Key Highlights
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on oncology and infectious diseases.
- The company's lead product candidate, birinapant, is a SMAC-mimetic designed to induce apoptosis in cancer cells.
- SHAPE, a proprietary HDAC inhibitor, is being developed for topical treatment of early-stage cutaneous T-cell lymphoma.
- TetraLogic has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore birinapant's potential in infectious diseases.
- The company's market capitalization is $0.00B, reflecting its early stage and the inherent risks of drug development.
Who Are TLOG's Competitors?
TLOG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TLOG's Key Strengths?
Proprietary SMAC-mimetic technology.
- Clinical-stage product candidates.
- Research collaboration with Walter and Eliza Hall Institute.
- Focus on unmet medical needs in oncology and infectious diseases.
What Are TLOG's Weaknesses?
Limited financial resources.
- Reliance on a small number of product candidates.
- High risk of clinical trial failure.
- OTC market listing.
What Are the Key Risks for TLOG?
Financial-distress signal — its Altman Z-Score of -10.60 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for birinapant or SHAPE.
- Regulatory setbacks in drug approval process.
- Competition from other biotechnology and pharmaceutical companies.
- Limited financial resources and need for additional funding.
- Risks associated with trading on the OTC market.
What Are TLOG's Competitive Advantages?
- Proprietary small molecule therapeutics platform.
- Patent protection for its drug candidates.
- Research collaborations with leading institutions.
- Expertise in apoptosis-inducing agents and HDAC inhibitors.
What Does TLOG Do?
TetraLogic Pharmaceuticals Corporation, established in 2001 and headquartered in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of small molecule therapeutics. The company's primary focus is on addressing unmet medical needs in oncology and infectious diseases. TetraLogic was formerly known as Gentara Corporation before rebranding in January 2006. Their lead product candidates include birinapant, a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC-mimetic), designed to induce apoptosis or cell death in damaged cells. Birinapant is being explored for its potential in various cancer treatments. The company is also developing SHAPE, a proprietary histone deacetylase (HDAC) inhibitor intended for topical use in the treatment of early-stage cutaneous T-cell lymphoma (CTCL). SHAPE represents a targeted approach to address the localized manifestations of CTCL. TetraLogic has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to investigate SMAC-mimetics, including birinapant, in the treatment of infectious diseases, expanding the potential application of their core technology. The company operates with a team of 29 employees, reflecting its focus on research and development activities.
What Products and Services Does TLOG Offer?
- Discovers and develops small molecule therapeutics.
- Focuses on oncology and infectious diseases.
- Develops Second Mitochondrial Activator of Caspases-mimetics (SMAC-mimetics).
- Develops Histone Deacetylase Inhibitors (HDAC).
- Conducts clinical trials for its product candidates.
- Collaborates with research institutions to expand its therapeutic applications.
- Seeks to create therapies that induce apoptosis in damaged cells.
How Does TLOG Make Money?
- Develops and patents small molecule therapeutics.
- Conducts preclinical and clinical research to evaluate drug candidates.
- Seeks regulatory approval from agencies like the FDA.
- Potentially out-licenses or partners with larger pharmaceutical companies for commercialization.
What Industry Does TLOG Operate In?
TetraLogic Pharmaceuticals Corporation operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high levels of risk. The industry is driven by innovation and the pursuit of novel therapies for unmet medical needs. Companies like TetraLogic face competition from both large pharmaceutical companies and other smaller biotech firms. The success of companies in this sector depends on their ability to develop and commercialize innovative products, secure regulatory approvals, and establish strategic partnerships. Market trends include a growing focus on personalized medicine, targeted therapies, and immuno-oncology. The biotechnology industry is experiencing growth, fueled by increasing healthcare expenditures and technological advancements.
Who Are TLOG's Key Customers?
- Patients with cancer.
- Patients with cutaneous T-cell lymphoma.
- Potential pharmaceutical partners.
- Research institutions.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 2 sales, 10 other transactions · 10 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Earnings Track Record
TetraLogic Pharmaceuticals Corporation has missed Wall Street's EPS estimate in 2 of its last 3 reported quarters — a mixed record worth weighing. Reported results have landed about 17.2% below estimates on average.
Financial Health
TetraLogic Pharmaceuticals Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.60 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -87.6%, showing how much profit it generates from its asset base. A current ratio of 6.00 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
TetraLogic Pharmaceuticals Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Yigong Shi. TLOG has traded publicly since 2013.
TLOG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
TLOG Latest News
No recent news available for TLOG.
TLOG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for TLOG.
Price Targets
Wall Street price target analysis for TLOG.
TLOG MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for TLOG; grades run from A+ (80-100) to F (below 30).
Leadership: Yigong Shi
CEO
Without source data, I cannot provide a detailed biography, including career history, education, previous roles, or credentials.
Track Record: Information on Yigong Shi's track record is not available in the provided data. I am unable to provide details on key achievements, strategic decisions, or company milestones under his leadership due to the absence of source material.
TLOG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that TetraLogic Pharmaceuticals Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Trading on the OTC Other tier typically involves higher risks and less regulatory oversight compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Understand the company's capital structure and funding requirements.
- Review any available news articles or press releases about the company.
- Consult with a financial advisor before investing.
- Company has been in operation since 2001.
- Focus on clinical-stage drug development.
- Research collaboration with Walter and Eliza Hall Institute.
- Development of patented technologies.
TLOG Healthcare Stock FAQ
What do analysts say about TLOG stock?
The company's market capitalization is $0.00B, reflecting its early stage and the inherent risks of drug development. Investors should conduct their own thorough research and consider the company's financial condition, clinical trial progress, and regulatory outlook before making any investment decisions.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- OTC market data may be limited and less reliable than exchange-listed data.